A recent study indicates that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds far faster than those who end conventional lifestyle plans.
Research printed in a leading medical journal demonstrates that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these drugs should be cognizant of the danger of quick weight regain when the medication is stopped," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight within about one and a half years.
Weighing Therapies
The study, which examined 37 of studies involving over 9,000 of patients, compared the results of these new drugs with conventional dieting.
The team emphasize that individuals who lose weight through lifestyle changes alone typically have a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Fast Rebound
Doctors suggest the mechanism of the jabs accounts for the amplified regain.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of the hormone levels several times higher than normal could lead to the body to produce less of its endogenous hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making excessive eating far more likely."
An Ongoing Disease?
Health authorities advise the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts argue that, due to the significant potential of relapse, the treatment is often life-long.
This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the chronic character of excess weight," similar to managing diseases like high blood pressure.
Patient Testimonies
Users who have discontinued the medication explain a sudden return of cravings.
"It felt as if a switch flipping and I was suddenly extremely hungry," said a patient.
This challenge is exacerbated if users have not adopted permanent dietary or behavioural changes during therapy.
Significant Interest
Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is higher among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and lasting health benefits hinges on integrated lifestyle support.
